Evidence hub

Lupus (SLE): cell-therapy evidence by therapy class

Across every stem-cell intervention, ClinicalTrials.gov holds 44 registered records for Lupus (SLE) — 5 recruiting, 4 at Phase 3 or 4, in 10 countries. Snapshot 2026-08-29.

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The condition, and why cells are proposed

Systemic lupus erythematosus is autoimmunity against nuclear antigens with relapsing multi-organ involvement. Two lines exist: mesenchymal immunomodulation, and immune reset through haematopoietic transplantation or CAR-T, the latter producing the most striking recent case series in autoimmunity. Those are radically different risk-benefit propositions.

Therapy classes side by side

Therapy classRegisteredRecruitingPhase 3/4Countries
MSC21317
HSCT17214
exosomes2002
PRP0000

Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.

Geography of the research

United States accounts for about 42% of country mentions among sampled studies; 10 countries host at least one site.

CountryStudies with a site there
United States17
China11
South Korea3
France2
Brazil2
Belarus1
Spain1
Germany1

The largest registered studies

Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.

StudyPhaseStatusPlanned nLead sponsorStart
NCT04870333 — PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -VPhase 2, Phase 3Completed2,240Cambridge University Hospitals NHS Foundation Trust2021-02-19
NCT03580291 — Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)Phase 2Unknown230Lingyun Sun2018-08-01
NCT06888973 — Mesenchymal Stem Cells Infusion in Patients With Autoimmune DiseasesPhase 1, Phase 2Enrolling By Invitation200National Institute of Blood and Marrow Transplant (NIBMT), P2025-02-01
NCT06485648 — Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus NephritisEarly Phase 1Not Yet Recruiting96Chinese PLA General Hospital2024-10-01
NCT02633163 — Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)Phase 2Completed81Medical University of South Carolina2018-11-18
NCT06058078 — RY_SW01 Cell Injection Therapy in Active Lupus NephritisPhase 2Recruiting60Jiangsu Renocell Biotech Company2023-08-17

Most recently registered

StudyPhaseStatusPlanned nLead sponsorStart
NCT05029336 — Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseasesn/aRecruitingn/aStephan Grupp MD PhD2026-03
NCT07301164 — Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseasesn/aNot Yet Recruitingn/aPeking University Third Hospital2025-12-11
NCT07041801 — Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cellsn/aRecruitingn/aShenzhen Beike Bio-Technology Co., Ltd.2025-06-28
NCT06255028 — A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseasesn/aActive Not Recruitingn/aCentury Therapeutics, Inc.2025-02-06
NCT06888973 — Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseasesn/aEnrolling By Invitationn/aNational Institute of Blood and Marrow Transplant (NIBMT), P2025-02-01

Reading this honestly

A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found. For Lupus (SLE) specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.

Frequently asked

How many stem-cell trials exist for Lupus (SLE)?

44 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 5 were recruiting.

Which therapy class is furthest along for Lupus (SLE)?

Ranked by Phase 3/4 records: MSC (1), HSCT (1), exosomes (0), PRP (0).

Does a recruiting trial mean I can be treated?

No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.